[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Michele van Vugt\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100615853","phase-2-sonlicromanol-in-post-covid-100615853",false,"NCT07298005","Sonlicromanol in Post-COVID","SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial","SON4PEM","Inclusion Criteria:\n\n* Post COVID according to WHO criteria and verified by post COVID physician\n* Post-exertional malaise (PEM) according to DSQ-PEM questionnaire\n* Bell's disability score 20-70%\n* Mild initial SARS-CoV-2 infection (no hospitalisation)\n* WHO performance score of 0 before initial SARS-CoV-2 infection\n\nExclusion Criteria:\n\n* Patients at risk for cardiac conduction disorders\n* History of clinical significant gastro-intestinal surgery or dysmotility that impairs the adsorption of the IMP\n* Clinically significant respiratory or cardiovascular disease\n* Unstable neurological disease\n* Clinically significant active psychiatric disorder that requires treatment\n* History of substance abuse\n* Active malignancy within the past 5 years\n* History of solid organ transplantation\n* Active HIV, hepatitis B or C infection\n* BMI \\\u003C 18.5 or \\> 35\n* Pregnancy or breastfeeding\n* Clinically relevant laboratory test value outside the reference range\n* Use of the following medication, unless stable for at least one month before study and remaining stable throughout the study: (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, amino acids, antioxidant supplements and any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, antivirals, amiodarone and NSAIDs)\n* Use of the following medication: any moderate or strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', HIV antivirals, grapefruit), strong CYP3A4 inducers ((including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort, pioglitazone, troglitazone) or any medication metabolized by CYP3A4 with a narrow therapeutic index, medication known to be substrate of Organic Cation Transporter 1 (OCT1) and organic cation transporter 2 (OCT2) or strong P-glycoprotein inhibitors (including amiodarone, azithromycin, captopril, clarithromycin, cyclosporine, piperine, quercetin, quinidine, quinine, reserpine, ritonavir, tariquidar, and verapamil).\n* Use of any medication known to affect cardiac repolarization unless QTc interval at screening is normal during stable treatment for a period of two weeks, or 5 half-lives","ALL","18 Years","65 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).",[28],"Post COVID Condition","RECRUITING","2026-04-07",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":22},"2026-04",{"date":37,"type":22},"2027-03",{"name":39,"class":40},"Michele van Vugt","OTHER",""]